Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
NCT04460911 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 317
Last updated 2024-01-11
Summary
By leveraging a community-based, cancer-specific electronic healthcare record for this study, we aim to understand treatment patterns and clinical outcomes among patients with HR+/HER2- mBC who received care within the context of a large community oncology network in the United States.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-10-19
- Primary Completion
- 2022-04-01
- Completion
- 2022-04-01
Countries
- United States
Study Locations
More Related Trials
-
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
NCT05155566 ·Status: COMPLETED
-
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
NCT04937660 ·Status: COMPLETED
-
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
NCT04524728 ·Status: COMPLETED
-
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
NCT04318223 ·Status: UNKNOWN ·Phase: PHASE2
-
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
NCT06495164 ·Status: ACTIVE_NOT_RECRUITING
-
A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer
NCT03560856 ·Status: UNKNOWN ·Phase: PHASE2
-
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
NCT02894398 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
NCT04060862 ·Status: TERMINATED ·Phase: PHASE1
-
Palbociclib With Everolimus + Exemestane In BC
NCT02871791 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
NCT02142868 ·Status: NO_LONGER_AVAILABLE
-
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
NCT02040857 ·Status: COMPLETED ·Phase: PHASE2
-
Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer
NCT02491983 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs
NCT06003114 ·Status: COMPLETED
-
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
NCT02679755 ·Status: COMPLETED ·Phase: PHASE4
-
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy
NCT05853432 ·Status: COMPLETED
-
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
NCT02600923 ·Status: COMPLETED ·Phase: PHASE3
-
Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China
NCT04526028 ·Status: UNKNOWN
-
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
NCT05806671 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
NCT04671615 ·Status: COMPLETED
-
Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC
NCT05000736 ·Status: UNKNOWN
-
Patterns of Prescribing and Monitoring of Palbociclib
NCT03285568 ·Status: COMPLETED
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965 ·Status: RECRUITING ·Phase: PHASE3
-
Palbociclib in Real World Practice
NCT03280303 ·Status: COMPLETED
-
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT05169567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3